Author:
Sueta Daisuke,Yamashita Yugo,Morimoto Takeshi,Muraoka Nao,Umetsu Michihisa,Nishimoto Yuji,Takada Takuma,Ogihara Yoshito,Nishikawa Tatsuya,Ikeda Nobutaka,Otsui Kazunori,Tsubata Yukari,Shoji Masaaki,Shikama Ayumi,Hosoi Yutaka,Tanabe Yasuhiro,Chatani Ryuki,Tsukahara Kengo,Nakanishi Naohiko,Kim Kitae,Ikeda Satoshi,Mo Makoto,Kimura Takeshi,Tsujita Kenichi
Reference32 articles.
1. Edoxaban for the treatment of cancer-associated venous thromboembolism;Raskob;N. Engl. J. Med.,2018
2. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer;Khorana;N. Engl. J. Med.,2019
3. Apixaban for the treatment of venous thromboembolism associated with cancer;Agnelli;N. Engl. J. Med.,2020
4. Direct Oral anticoagulants compared with Dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis;Riaz;Mayo Clin. Proc.,2022
5. T. Fujisaki, D. Sueta, E. Yamamoto, C. Buckley, G.S.d.C. Correia, J. Aronson, P.T.d. Lara, K. Fujisue, H. Usuku, K. Matsushita, R. Mehran, G.D. Dangas, K. Tsujita, Comparing anticoagulation strategies for venous thromboembolism associated with active cancer, JACC CardioOncology 0(0).